The Peptide Drug Conjugates Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Peptide Drug Conjugates Market?
The market size of the peptide drug conjugates has seen rapid expansion in recent years. It is expected to increase from $3.16 billion in 2024 to $3.68 billion in 2025, with a compound annual growth rate (CAGR) of 16.1%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Peptide Drug Conjugates Industry?
The projected market size for the Peptide Drug Conjugates Global Market in 2029 is expected to be $6.60 billion. The Compound Annual Growth Rate (CAGR) is anticipated to be 15.8%.
Download Your Free Sample of the 2025 Peptide Drug Conjugates Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Peptide Drug Conjugates Market?
The key drivers in the peptide drug conjugates market are:
• Rising prevalence of cancer worldwide
• Increasing demand for targeted cancer therapies
• Growing pipeline of peptide-based drug candidates
• Expansion of personalized medicine and rising interest in combination therapies
Global Market Segmentation: Identifying Major Peptide Drug Conjugates Industry Segments
The peptide drug conjugates market covered in this report is segmented –
1) By Type: Therapeutic, Diagnostic
2) By Therapy Area: Oncology, Immunology, Infectious Diseases, Other Therapy Areas
3) By Route of Administration: Intravenous, Subcutaneous, Other Routes Of Administration
4) By End User: Hospitals, Clinics, Pharmacies, Other End Users
Pre-order the 2025 Peptide Drug Conjugates Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Peptide Drug Conjugates Market?
The key trends in the peptide drug conjugates market are:
• Improved peptide synthesis techniques are setting a new trend in the market.
• Advancements in linker technologies are significantly shaping the market's future.
• The shift towards enhanced site-specific conjugation methods is a notable emerging trend.
• There is a rising trend for better tumor targeting capabilities and innovations in payload selection.
Who Are the Top Competitors & Leading Players in the Peptide Drug Conjugates Market?
Major players in the peptide drug conjugates market are:
• AstraZeneca PLC
• Novartis AG
• BioNTech SE
• Curium US LLC
• ADC Therapeutics SA
• PeptiDream Incorporated
• PepGen Corporation
• Theratechnologies Inc.
• Italfarmaco Società per Azioni
• Protagonist Therapeutics Inc.
• Alteogen Inc.
• Metsera Inc.
• Zealand Pharma A/S
• Apellis Pharmaceuticals Inc.
• Angiochem Inc.
• Cybrexa Therapeutics Inc.
• Ambrx Inc.
• Oncopeptides Aktiebolag (AB)
• ProteinQure Incorporated
• Soricimed Biopharma Inc.
• Esperance Pharmaceuticals Inc.
• Adcytherix SA
• Araris Biotech AG
Regional Dominance: Which Area Leads the Global Peptide Drug Conjugates Market?
North America was the largest region in the peptide drug conjugates market in 2024
